Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of prosetin in healthy volunteers and participants with ALS
NL-OMON61004Phase 1Active, not recruiting
- Sponsor
- ProJenX
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of prosetin in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by ProJenX. Started Jul 2024; status: active, not recruiting.
02
Drugs
prosetin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61004.